ASCO23 - LBA3000: Efficacy and safety T-DXd in HER2-expressing solid tumors: DESTINY-PanTumor02 ...

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Trastuzumab Deruxtecan: Effects in Multiple Cancer Types

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

T-DXd in HER2-Expressing Cancers Regardless of Tumor Location

Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology

DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

Antibody-drug conjugates in the treatment of solid tumors

Trastuzumab deruxtecan gives strong anti-tumour activity in multiple tumour types

【2025年以降も好業績 間違いなし】見逃し厳禁。 医薬品株 急成長トップ３

Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical Trials

Why HER2 IHC Testing is Important for Everyone with Cancer!

Immunotherapy, Novel Therapies, and Shared Decision-Making in Advanced Endometrial Cancer

ASCO 2023: Trastuzumab deruxtecan ottimi risultati su tumori solidi avanzati HER2 positivi

HER2 in Gastric Cancer

What Do We Need to Know About New Therapeutics for Patients With Endometrial Cancer?

Precision Oncology Update from ASCO and WCGIC 2023